Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 10 10:19AM ET
3.97
Dollar change
-0.03
Percentage change
-0.84
%
Index- P/E10.79 EPS (ttm)0.37 Insider Own2.90% Shs Outstand49.86M Perf Week-1.73%
Market Cap197.94M Forward P/E82.14 EPS next Y0.05 Insider Trans0.00% Shs Float48.42M Perf Month-24.09%
Income24.07M PEG- EPS next Q- Inst Own0.16% Short Float0.13% Perf Quarter-6.24%
Sales82.22M P/S2.41 EPS this Y165.13% Inst Trans22.10% Short Ratio4.27 Perf Half Y-28.27%
Book/sh2.08 P/B1.91 EPS next Y-88.17% ROA11.49% Short Interest0.06M Perf Year24.06%
Cash/sh1.33 P/C3.00 EPS next 5Y- ROE26.13% 52W Range3.31 - 6.42 Perf YTD3.12%
Dividend Est.- P/FCF- EPS past 5Y26.89% ROI14.35% 52W High-38.19% Beta1.13
Dividend TTM- Quick Ratio3.74 Sales past 5Y10584.96% Gross Margin- 52W Low19.94% ATR (14)0.18
Dividend Ex-Date- Current Ratio3.74 EPS Y/Y TTM166.79% Oper. Margin21.31% RSI (14)29.99 Volatility3.22% 3.06%
Employees159 Debt/Eq0.70 Sales Y/Y TTM243.10% Profit Margin29.27% Recom1.00 Target Price10.31
Option/ShortNo / Yes LT Debt/Eq0.62 EPS Q/Q- Payout- Rel Volume0.40 Prev Close4.00
Sales Surprise33.74% EPS Surprise77.46% Sales Q/Q- EarningsNov 07 AMC Avg Volume14.75K Price3.97
SMA20-7.46% SMA50-22.53% SMA200-8.61% Trades Volume1,020 Change-0.84%
Date Action Analyst Rating Change Price Target Change
Dec-20-21Upgrade H.C. Wainwright Neutral → Buy $8
Jul-23-20Upgrade Stifel Hold → Buy
Jun-25-20Initiated BofA/Merrill Underperform $7
May-13-20Downgrade Kepler Buy → Reduce
May-12-20Downgrade H.C. Wainwright Buy → Neutral $46 → $11
May-12-20Downgrade Barclays Overweight → Equal Weight $55 → $14
Oct-29-19Reiterated B. Riley FBR Buy $52 → $43
Jun-25-19Initiated Stifel Hold
Apr-24-19Initiated SVB Leerink Outperform $58
Apr-22-19Initiated Barclays Overweight
Nov-13-24 04:10PM
Nov-07-24 04:10PM
Sep-23-24 01:30AM
Sep-19-24 04:10PM
Jul-26-24 07:45AM
04:10PM Loading…
Jul-09-24 04:10PM
Jun-17-24 04:10PM
Jun-10-24 05:22PM
May-29-24 04:10PM
May-22-24 12:05PM
May-14-24 04:10PM
Apr-25-24 04:10PM
Apr-15-24 04:10PM
Apr-05-24 02:00PM
Apr-04-24 04:10PM
04:10PM Loading…
Feb-29-24 04:10PM
Jan-15-24 04:10PM
Jan-11-24 04:10PM
Dec-08-23 01:55AM
Dec-07-23 05:15AM
Dec-06-23 11:30AM
Nov-16-23 04:10PM
Nov-13-23 04:30PM
Nov-09-23 04:10PM
Nov-02-23 05:10PM
Sep-26-23 04:10PM
Sep-20-23 04:10PM
Sep-05-23 04:10PM
Aug-10-23 04:10PM
Jul-12-23 04:10PM
01:00AM Loading…
Jun-30-23 01:00AM
Jun-07-23 04:10PM
May-31-23 04:44PM
04:10PM
May-24-23 01:00PM
May-23-23 04:10PM
May-11-23 04:10PM
May-09-23 04:10PM
Apr-27-23 04:10PM
Apr-19-23 04:10PM
Apr-18-23 04:10PM
Apr-13-23 04:10PM
Feb-28-23 04:10PM
Jan-30-23 04:10PM
Jan-24-23 04:10PM
Jan-05-23 04:10PM
Nov-17-22 04:10PM
Nov-10-22 04:10PM
Oct-25-22 04:10PM
Sep-29-22 04:10PM
Sep-28-22 04:10PM
Sep-19-22 12:42PM
01:30AM
Sep-13-22 04:10PM
Jul-08-22 04:10PM
11:12AM
May-25-22 04:10PM
May-11-22 04:10PM
Apr-29-22 04:10PM
Apr-20-22 04:10PM
Apr-14-22 12:00PM
Apr-07-22 04:10PM
Feb-28-22 04:10PM
Jan-24-22 04:10PM
Jan-21-22 04:10PM
Jan-11-22 10:00AM
Dec-23-21 10:00AM
Dec-17-21 11:42AM
06:25AM
01:15AM
01:00AM
01:00AM
Nov-18-21 04:15PM
Nov-09-21 04:10PM
Nov-08-21 04:10PM
Nov-02-21 05:10PM
Sep-29-21 04:10PM
Jul-09-21 04:10PM
Jun-30-21 04:10PM
Jun-24-21 04:10PM
Jun-23-21 04:10PM
Jun-18-21 12:52PM
Jun-15-21 04:10PM
May-27-21 04:10PM
May-12-21 04:10PM
May-11-21 04:10PM
May-10-21 04:10PM
May-03-21 02:10AM
Apr-23-21 12:30PM
Apr-22-21 04:10PM
Apr-01-21 04:10PM
Mar-04-21 04:10PM
Mar-01-21 04:05PM
Feb-26-21 04:10PM
Feb-23-21 10:50AM
Feb-22-21 04:10PM
Feb-18-21 05:00PM
Feb-12-21 05:00PM
Feb-10-21 04:10PM
12:16PM
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver. The company was founded by Jean-Francois Mouney, Florence Sejourne, and Bart Staels in September 1999 and is headquartered in Loos, France.